A phase 1 study of SCB-808 for the treatment of rheumatoid arthritis and other autoimmune diseases in china.

Trial Profile

A phase 1 study of SCB-808 for the treatment of rheumatoid arthritis and other autoimmune diseases in china.

Planning
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Clover Biopharmaceuticals
  • Most Recent Events

    • 28 Dec 2017 New trial record
    • 22 Dec 2017 According to a Clover Biopharmaceuticals media release, company has received Clinical Trial Application (CTA) approval from the Chinese Food and Drug Administration (CFDA) to conduct the clinical trials for SCB-808 in China. This trial is expect to initiate in mid 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top